NRX Pharmaceuticals Inc <NRXP.OQ> expected to post a loss of 30 cents a share - Earnings Preview
NRX Pharmaceuticals Inc NRXP.OQ NRXP.O is expected to show a rise in quarterly revenue when it reports results on May 15 for the period ending March 31 2025
The Wilmington Delaware-based company is expected to report revenue of $1.138 million, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for NRX Pharmaceuticals Inc is for a loss of 30 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for NRX Pharmaceuticals Inc is $25.00, above its last closing price of $2.08.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.31 | -0.32 | -0.77 | Missed | -143.2 |
Sep. 30 2024 | -0.59 | -0.64 | -0.13 | Beat | 79.7 |
Jun. 30 2024 | -0.68 | -0.69 | -0.67 | Beat | 3.6 |
Mar. 31 2024 | -0.55 | -0.55 | -0.74 | Missed | -34.5 |
Dec. 31 2023 | -0.63 | -0.70 | -0.50 | Beat | 28.6 |
Sep. 30 2023 | -1.15 | -1.13 | -0.70 | Beat | 38.2 |
Jun. 30 2023 | -1.50 | -1.37 | -1.20 | Beat | 12.2 |
Mar. 31 2023 | -1.40 | -1.40 | -1.60 | Missed | -14.3 |
This summary was machine generated May 13 at 20:26 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Related Articles
Tencent Q1 2025 Earnings Preview: A Critical Inflection Below the Surface
TradingKey - As Tencent (TCEHY) is set to report Q1 2025 earnings today after the market close, the market's eyes remain on macro headwinds-China's slow-moving consumer recovery, regulation overhangs, and the unfolding AI race. But the more compelling fundamental narrative below the surface is that
Elon Musk in Politics for Three Months – Did “Tesla Killers” Really Have a Happy Q1?
TradingKey – Tesla (TSLA.US) remains the dominant force in the U.S. and global electric vehicle (EV) market. However, with Elon Musk’s transition to head the Department of Government Efficiency (DOGE), anti-Tesla sentiment surged across the U.S. and Europe — offering opportunities for Tesla killers.
Walmart (WMT) Q1 2026 Earnings Preview: What to Expect from the Retail Giant’s Earnings?
Walmart will report its first quarterly earnings for this fiscal year on Thursday, after the bell. As one of the largest retailers in the country, Walmart results can serve as a reliable proxy for grasping the US consumer sentiment, especially in the context of the recent economic woes.
Apple’s Strategic Evolution in Q2 FY25
TradingKey - Apple (AAPL) has long excelled at the nexus of hardware greatness, software integration, and brand affection. But Q2 FY25 presents a picture of a grownup goliath honing its operating playbook while building the foundation for future expansion outside of devices.
